Alzinova
1.874 SEK +0.11%Be the first to follow this company
Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg.
Revenue
270K
EBIT %
-6,118.52 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ALZ
Daily low / high price
1.846 / 1.9
SEK
Market cap
83.45M SEK
Turnover
104.06K SEK
Volume
56K
Financial calendar
Interim report
2024-05-28
General meeting
2024-05-29
Interim report
2024-08-22
Interim report
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Maida Vale Capital | 15.2 % | 15.2 % |
Försäkrings AB Avanza Pension | 7.0 % | 7.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Alzinova: Fördjupad analys påvisar positiv trend för biomarkörer
Alzinova: In-depth analysis shows positive trend in biomarkers
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools